Raphael Pharmaceutical Inc. reported a net loss of approximately $1.28 million for the fiscal year ending December 31, 2025, a decrease from a loss of $1.52 million in the previous year. The company's operating expenses totaled $1.25 million, down from $1.51 million in 2024, primarily due to reduced research and development costs, which fell by 18.6% to $631,000. General and administrative expenses also decreased by 16.23% to $614,000, reflecting lower professional service fees. The basic and diluted net loss per share was $0.07, compared to $0.08 in the prior year.
In terms of strategic developments, Raphael Pharmaceutical has made significant progress in its clinical research. The company completed a proof-of-concept study for its lead product candidate targeting rheumatoid arthritis (RA) in December 2024, which showed promising results. Following this, in August 2025, the company launched its proprietary natural formula under the "RaphaWell" brand, aimed at supporting RA patients in the U.S. This product is positioned as a clinically tested dietary supplement and is part of the company's broader strategy to address unmet medical needs in autoimmune diseases.
Operationally, Raphael Pharmaceutical has focused on expanding its research capabilities and product pipeline. The company is currently developing a novel treatment for asthma and has conducted studies using human-derived immune cells and mouse models to explore the effects of cannabinoids on various conditions, including COVID-19. The company has also filed a provisional patent application for its cannabinoid-based technology platform, which targets neutrophil-dominant autoimmune diseases, including RA and psoriatic arthritis.
Despite these advancements, the company faces challenges, particularly regarding its financial position. As of December 31, 2025, Raphael Pharmaceutical reported cash and cash equivalents of only $45,000, raising concerns about its ability to fund ongoing operations. The company anticipates needing approximately $1 million for research and development activities and another $1 million for capital expenditures over the next 12 months. Management has indicated that additional financing will be necessary to support its operations and product development efforts, which may not be readily available.
Looking ahead, Raphael Pharmaceutical aims to continue refining its product candidates and pursuing regulatory approvals from the FDA and other international agencies. The company is committed to leveraging its research partnerships and expertise in cannabinoid therapies to develop innovative solutions for patients with inflammatory and autoimmune conditions. However, the uncertainty surrounding its financial stability and the regulatory landscape poses significant risks to its future operations and growth potential.
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. is a biotech company specializing in the discovery and development of cannabinoid-based therapies for autoimmune, inflammatory, and respiratory conditions. Its core focus is on developing CBD-derived drug candidates for rheumatoid arthritis, COVID-19-related hyperinflammation, and asthma. The company collaborates with research institutions, relies on third-party manufacturing, and aims to obtain regulatory approvals for innovative, plant-based medicines targeting unmet medical needs worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.